HER2-NEGATIVE BREAST CARCINOMA
Clinical trials for HER2-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tame metastatic breast cancer
Disease control Recruiting nowThis early-phase study is for people with metastatic HR+ HER2- breast cancer that has spread to the bone. Researchers want to find the best dose of the drug abemaciclib when given together with radiation and hormone therapy. The goal is to control the disease and manage side effe…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:36 UTC
-
New hope for advanced breast cancer: OPERA-02 trial tests promising drug combo
Disease control Recruiting nowThis phase 3 study tests whether a new drug called palazestrant, combined with ribociclib, works better than the standard treatment (letrozole plus ribociclib) for people with a common type of advanced breast cancer (ER+/HER2-). About 1,000 adults who have not had prior treatment…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control Recruiting nowThis study tests a new drug, OP-1250, against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can delay cancer growth better than standard care. About 510 adults whose…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Stem cell combo trial aims to outsmart Drug-Resistant cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with metastatic pancreatic or breast cancer that has stopped responding to standard therapies. The treatment combines two chemotherapy drugs with high-dose vitamins and a stem cell transplant to help the body recover. The ma…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Immunotherapy boost may stop High-Risk breast cancer return
Disease control Recruiting nowThis large phase III trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from coming back in people with a high-risk form of hormone receptor-positive, HER2-negative breast cancer (called MammaPrint High 2 Risk). About 3…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Turkey tail mushrooms tested as breast cancer treatment in new trial
Disease control Recruiting nowThis study tests whether turkey tail mushrooms can slow or shrink breast tumors in post-menopausal women with a common type of breast cancer (HER2-negative, ER-positive). About 40 women will take the mushroom supplement between diagnosis and surgery. The main goal is to see if th…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Can adding radiation before surgery boost immune response in aggressive breast cancer?
Disease control Recruiting nowThis study is for people with operable, lymph node-positive triple negative breast cancer. It tests whether giving a low or high dose of radiation to the breast tumor along with immunotherapy (pembrolizumab) before standard chemotherapy can improve the chance of eliminating all c…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Hormone therapy before surgery may reduce cancer left behind in breast cancer patients
Disease control Recruiting nowThis study looks at whether giving hormone therapy before surgery helps women with a certain type of breast cancer (invasive lobular carcinoma) have cleaner surgical results. The goal is to see if this approach lowers the chance of cancer cells being found at the edges of removed…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
Smart bag and texts boost pill-taking in advanced breast cancer
Symptom relief Recruiting nowThis study tests whether a connected platform (a special medication bag called WiseBag plus text reminders) helps people with metastatic breast cancer take their CDK4/6 inhibitor pills more consistently. About 410 patients will either use the bag alone or the bag with text alerts…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated May 16, 2026 23:38 UTC
-
Acupuncture may help black women avoid debilitating joint pain during breast cancer treatment
Symptom relief Recruiting nowThis study tests whether in-person acupuncture or virtual acupressure can prevent joint pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. It focuses on Non-Hispanic Black postmenopausal women with early-stage breast cancer, who are more likely to st…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Symptom relief
Last updated May 16, 2026 23:38 UTC
-
Gentler chemo for seniors: DOROTHY trial aims to cut toxicity without sacrificing results
Symptom relief Recruiting nowThis study is for women aged 65 and older with early-stage HER2-negative breast cancer. It tests whether a lower dose of the chemotherapy drugs docetaxel and cyclophosphamide can still be effective while causing fewer side effects and improving quality of life. About 174 particip…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated May 15, 2026 11:57 UTC
-
Stress relief program tested for triple negative breast cancer patients
Symptom relief Recruiting nowThis study tests whether a 10-week stress reduction program is doable and helpful for women with early-stage triple negative breast cancer. The program teaches relaxation, coping skills, and problem-solving, and also connects patients with social services for needs like transport…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated May 15, 2026 11:57 UTC
-
New study tracks Real-World impact of targeted cancer drugs in advanced breast cancer
Knowledge-focused Recruiting nowThis study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these treatments control the cancer in real-world settings. The goal is to gather information…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC